NASDAQ: GRAL · IEX Real-Time Price · USD
+0.66 (4.49%)
Jul 15, 2024, 12:52 PM EDT - Market open
Market Cap 478.29M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 31.05M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 648,963
Open 15.00
Previous Close 14.81
Day's Range 14.91 - 15.59
52-Week Range 12.51 - 23.36
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Aug 15, 2024

About GRAL

GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. GRAIL, LLC was formerly known as PSC15, Inc. and changed its name to GRAIL, LLC in January 2016. The company was incorporated in 2... [Read more]

Sector Healthcare
Founded 2016
Country Canada
Stock Exchange NASDAQ
Ticker Symbol GRAL
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements


GRAIL Advances the Galleri® Registrational Clinical Trial Program

GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study;  Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visit...

9 hours ago - PRNewsWire

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.

Other symbols: ILMN
17 days ago - Reuters

Illumina Completes Spin-Off Of GRAIL

On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitaliz...

Other symbols: ILMN
18 days ago - Forbes

Grail's shares fall in Nasdaq debut after spin-off from Illumina

Shares of Grail fell as much as 11.7% in their market debut on Tuesday after being spun out of gene-sequencing company Illumina.

20 days ago - Reuters

Grail expected to be first FDA-approved multi-cancer test, says CEO Bob Ragusa

Grail CEO Bob Ragusa joins CNBC's 'Squawk Box' to discuss the company's debut on the Nasdaq, how Grail is innovating early cancer detection, and more.

20 days ago - CNBC Television

Grail bets big on flagship cancer test after spin-off from Illumina

U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina , is betting that commercial partnerships with health systems, employers a...

Other symbols: ILMN
20 days ago - Reuters

GRAIL to Begin Trading on the Nasdaq Stock Exchange

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC) will be listed and commence regular-way trading on the Nasdaq as of tomorrow, June 25, 2024.

20 days ago - Business Wire